Statins and prostate cancer prevention:: where we are now, and future directions

被引:54
作者
Murtola, Teemu J. [1 ]
Visakorpi, Tapio [2 ]
Lahtela, Jorma [3 ]
Syvala, Heimo [4 ]
Tammela, Teuvo L. J. [5 ]
机构
[1] Univ Tampere, Sch Publ Hlth, Dept Epidemiol, FIN-33014 Tampere, Finland
[2] Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland
[3] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland
[4] Univ Tampere, Dept Anat, FIN-33101 Tampere, Finland
[5] Tampere Univ Hosp, Dept Urol, Tampere, Finland
来源
NATURE CLINICAL PRACTICE UROLOGY | 2008年 / 5卷 / 07期
关键词
anticarcinogenic agent; prostatic neoplasm; PSA; statin;
D O I
10.1038/ncpuro1146
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Statins are cholesterol-lowering drugs that are widely used to prevent and treat atherosclerotic cardiovascular disease. Recent research from both in vitro and in vivo studies suggests that there is an association between the use of statins and a reduction in the incidence of and mortality from prostate cancer. Several mechanisms of action that might bring about these beneficial effects of statins have been proposed, most of which include direct effects of statins on intracellular signaling. In this Review we discuss the current knowledge on the use of statins to prevent prostate cancer. We will also look at future directions for clinical research on this topic.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 65 条
[1]   Pleiotropic effects of statins and related pharmacological experimental approaches [J].
Alegret, M. ;
Silvestre, J. S. .
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2006, 28 (09) :627-656
[2]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[3]   Long-term persistence in use of statin therapy in elderly patients [J].
Benner, JS ;
Glynn, RJ ;
Mogun, H ;
Neumann, PJ ;
Weinstein, MC ;
Avorn, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04) :455-461
[4]   3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer -: A nested case-control study [J].
Blais, L ;
Desgagné, A ;
LeLorier, J .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (15) :2363-2368
[5]   Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer [J].
Bravi, F ;
Scotti, L ;
Bosetti, C ;
Talamini, R ;
Negri, E ;
Montella, M ;
Franceschi, S ;
La Vecchia, C .
ANNALS OF ONCOLOGY, 2006, 17 (06) :1014-1017
[6]   Statins and risk of cancer: A systematic review and metaanalysis [J].
Browning, Danielle R. L. ;
Martin, Richard M. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (04) :833-843
[7]   Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario [J].
Carruba, Giuseppe .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 102 (04) :899-911
[8]   Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening [J].
Ciatto, S ;
Zappa, M ;
Villers, A ;
Paez, A ;
Otto, S ;
Auvinen, A .
BJU INTERNATIONAL, 2003, 92 :97-100
[9]  
COLLI JL, UROL ONCOL IN PRESS
[10]   Statin use and the risk of 10 cancers [J].
Coogan, Patricia F. ;
Rosenberg, Lynn ;
Strom, Brian L. .
EPIDEMIOLOGY, 2007, 18 (02) :213-219